Shares of Procter & Gamble are trading near their lowest levels in five years after a 12-month decline of approximately 23%. The market has largely priced in the slowest organic sales growth in P&G’s history—management guided to mid single-digit revenue growth for fiscal 2026 versus flat growth in the prior year. Despite this headwind, the company generated operating cash flow of $15.4 billion in fiscal 2025 and sustained a net margin of 19.3%. Free cash flow coverage remains strong, supporting the firm’s 4.2% annual dividend yield. At current valuation multiples—17x trailing earnings—investors are paying below the five-year average multiple of 19x, suggesting a valuation cushion should growth reaccelerate.

In its latest 13F filing, GDS Wealth Management disclosed a 20.9% increase in its Procter & Gamble stake during the third quarter. The firm added 14,060 shares, bringing its total to 81,190 shares valued at $12.48 million at period end. Other institutional moves included BAM Wealth Management’s initiation of a new $678,000 position and PFG Investments raising its holding by 1.6% to 54,237 shares valued at $8.33 million. Overall, hedge funds and institutions now control 65.8% of the company’s outstanding shares, reflecting continued confidence in P&G’s long-term cash generation and dividend track record.

Equity research teams have adjusted their outlooks on P&G ahead of the February earnings release. Three major banks raised their ratings—JPMorgan upgraded to overweight, UBS increased its target by 5.6%, and Wells Fargo lifted its objective to reflect a 2.1% dividend yield. Conversely, Raymond James trimmed its price target by 5.4% but retained an outperform stance. Fourteen analysts now rate the stock a buy, eight call it a hold, and the consensus 12-month target implies nearly 11% upside from current levels. The average earnings per share estimate for fiscal 2026 stands at $6.91, representing 3.5% year-over-year growth driven by pricing initiatives and cost savings.